semaglutide cardiovascular risk Effects of on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6 π¨ Breaking News: Real-World Data
Description
Clinical trials have demonstrated that semaglutide can reduce hemoglobin A1c by 1.52.0% in patients with type 2 diabetes (SUSTAIN clinical trial program) and produce weight loss of 1015% of body weight over 68 weeks in obesity treatment (STEP clinical trial program)
Arthur Luxenberg
Article Summary GLP-1 medications like semaglutide have transformed obesity and diabetes treatment, helping millions lose weight and improve metabolic health
Gastrointestinal side effects associated with Zepbound, particularly nausea and vomiting, may occasionally trigger autonomic responses including diaphoresis (sweating)
